Related references
Note: Only part of the references are listed.A Consensus Molecular Classification of Muscle-invasive Bladder Cancer
Aurelie Kamoun et al.
EUROPEAN UROLOGY (2020)
Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma
Y. Loriot et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Prognostic significance of epidermal growth factor receptor (EGFR) over expression in urothelial carcinoma of urinary bladder
Atif Ali Hashmi et al.
BMC UROLOGY (2018)
Bladder Cancer Molecular Taxonomy: Summary from a Consensus Meeting
Seth P. Lerner et al.
BLADDER CANCER (2016)
A Randomized Phase 2 Trial of Gemcitabine/Cisplatin With or Without Cetuximab in Patients With Advanced Urothelial Carcinoma
Maha Hussain et al.
CANCER (2014)
EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype
Sandra Rebouissou et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Risk of venous and arterial thromboembolic events associated with anti-EGFR agents: a meta-analysis of randomized clinical trials
F. Petrelli et al.
ANNALS OF ONCOLOGY (2012)
Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer
Nuria Juanpere et al.
HUMAN PATHOLOGY (2012)
Phase II Trial of Cetuximab With or Without Paclitaxel in Patients With Advanced Urothelial Tract Carcinoma
Yu-Ning Wong et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Randomized Phase II/III Trial Assessing Gemcitabine/Carboplatin and Methotrexate/Carboplatin/Vinblastine in Patients With Advanced Urothelial Cancer Who Are Unfit for Cisplatin-Based Chemotherapy: EORTC Study 30986
Maria De Santis et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Long-term-survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer (vol 17, pg v118, 2006)
Hans von der Maase et al.
ANNALS OF ONCOLOGY (2011)
KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab
Astrid Lievre et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours
CN Sternberg et al.
EUROPEAN JOURNAL OF CANCER (2006)
Long-term-survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer
H von der Maase et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Share Paper
